HOPE by SOLTI is a leading real-world clinical practice study in Spain that assesses the impact of using comprehensive genomic data on treatment decision-making for patients with locally advanced or metastatic breast cancer. It is highly relevant for its patient empowerment approach that has exceeded participation expectations.
Industry: Biomedical Research
DIPCAN aims to change clinical practice in the area of oncology by combining clinical, imaging, anatomopathological, and genomic data to identify certain patients who could be more likely to better respond to treatment. Genomcore provides its technological framework to process and integrate all datasets into a single database for AI model development.
The AGATA study is the first genomic screening platform for advanced breast cancer ever attempted in Spain. By this molecular platform SOLTI aimed to increase the likelihood of a patient being included in a targeted clinical trial based on the tumor molecular profiling. Genomcore provided a secure and compliant federated platform to store and analyze the clinical and genomic data within the project.